Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Affymetrix, Inc.    AFFX

Delayed Quote. Delayed  - 03/31 10:00:00 pm
14.01 USD   +0.14%
04/05 AFFYMETRIX : Receives a Hold from Cantor Fitzgerald (Cantor Bryan Br..
04/01 AFFYMETRIX : Grant Supports Outcomes Research for Noninvasive Genomi..
03/31DJTHERMO FISHER S : Completes Acquisition of Affymetrix
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

Affymetrix, Inc. : Wall Street Fundamentals Releases New In-Depth Stock Reports on AFFX, CATM, RGR and TRLA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/02/2013 | 02:35pm CEST

Global markets rallied on positive economic data from the U.S. and China, sending the S&P 500 Index above the 1700 mark for the first time Thursday. Both the S&P 500 Index and the Down Jones have posted gains of approximately 19 percent year-to-date, while the Nasdaq and Russell 2000 have posted gains of roughly 21 percent and 25 percent, respectively. On Thursday, reports showed jobless claims in the U.S. declined 19,000 to $326,000, the lowest since January 2008. Additionally, the official China Manufacturing Purchasing Managers' for July increased to 50.3 from 50.1 in the previous month, any reading above 50 signals growth from the previous month.

Affymetrix, Inc. (NASDAQ: AFFX) shares traded in the range of $4.17 to $4.37 Thursday before settling to close at $4.32, an increase of 13.68 percent. The stock appears to be facing some resistance at the $44.28 and $4.47 level with some support at $4.12. The company reported second quarter revenues increased 20.0 percent year-over-year to $79.5 million. Shares of Affymetrix have gained approximately 36.0 percent year-to-date.

More information on Affymetrix and access to the free equity report can be found at:
www.WallStreetFundamentals.com/AFFX

Cardtronics, Inc. (NASDAQ: CATM) shares traded in the range of $29.80 to $33.26 Thursday before settling to close at $33.03, an increase of 12.10 percent. The stock appears to have some support at the $30.63 and $29.92 levels. The company reported second quarter adjusted Net Income per diluted share increased 29 percent year-over-year to $0.49. Shares of Cardtronics have gained approximately 39.0 percent year-to-date.

More information on Cardtronics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CATM

Sturm, Ruger & Company (NYSE: RGR) shares traded in the range of $52.62 to $55.40 Thursday before settling to close at $52.69, an increase of 3.58 percent. The stock appears to be facing some resistance at the $55.69 and $57.90 level with some support at $51.94. The company reported earnings in the second quarter grew 79 percent when compared to a year ago. Shares of Sturm, Ruger & Company have gained approximately 16.0 percent year-to-date.

More information on Sturm, Ruger & Company and access to the free equity report can be found at:
www.WallStreetFundamentals.com/RGR

Trulia Inc. (NYSE: TRLA) shares traded in the range of $42.24 to $47.97 Thursday before settling to close at $44.53, an increase of 19.51 percent. The stock appears to have some support at the $42.25 and $39.65 levels. The company reported second quarter revenues increased 77 percent year-over-year to $29.7 million. Shares of Trulia have gained approximately 174.0 percent year-to-date.

More information on Trulia and access to the free equity report can be found at:
www.WallStreetFundamentals.com/TRLA

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AFFYMETRIX, INC.
04/05 AFFYMETRIX : Receives a Hold from Cantor Fitzgerald (Cantor Bryan Brokmeier Comm..
04/01 AFFYMETRIX : Grant Supports Outcomes Research for Noninvasive Genomic Profiling
03/31 AFFYMETRIX : Entry into a Material Definitive Agreement, Termination of a Materi..
03/31 AFFYMETRIX : Determines Unsolicited Proposal from Origin Technologies Could Lead..
03/31DJTHERMO FISHER SCIENTIFIC : Completes Acquisition of Affymetrix
03/31DJTHERMO FISHER SCIENTIFIC : Completes Acquisition of Affymetrix
03/31 AFFYMETRIX : Origin Significantly Enhances All-Cash Offer for Affymetrix
03/31 AFFYMETRIX : Former Affymetrix Senior Executives Propose to Acquire Affymetrix f..
03/30 AFFYMETRIX : Faruqi & Faruqi, LLP : Announces Filing of a Class Action Lawsuit A..
03/29 THERMO FISHER SCIENTIFIC : Affymetrix Reaffirms Support For Thermo Fisher Merger..
More news
Sector news : Bio Diagnostics & Testing
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
More sector news : Bio Diagnostics & Testing
News from SeekingAlpha
04/02 WEEK IN REVIEW : Deals Dominate China Biopharma News
03/31 IBM Buys Salesforce.com Cloud Consultant
03/30 30% Annual Return From This Stock
03/29 *Except For Amazon
03/29 WALL STREET BREAKFAST : Yellen Speech Takes Center Stage
Advertisement
Chart AFFYMETRIX, INC.
Duration : Period :
Affymetrix, Inc. Technical Analysis Chart | AFFX | US00826T1088 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Managers
NameTitle
Jami K. Dover Nachtsheim Chairman
Andrew J. Last Chief Operating Officer & Executive Vice President
Robert H. Trice Independent Director
Gary S. Guthart Independent Director
Merilee Raines Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AFFYMETRIX, INC.38.85%0
MIRACA HOLDINGS INC.-2.06%2 962
BEIJING STRONG BIOTECH..--.--%1 720
SEEGENE INC--.--%896
INNATE PHARMA-18.46%668
LION BIOTECHNOLOGIES I..3.50%468
More Results